Zimbabwe has declined a significant US health deal worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive biological samples.
The decision was revealed following a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson later stated that the United States was demanding access to biological samples for research and commercial purposes while refused to share the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more negotiations to reach a agreement agreeable to all parties so the country's vital HIV programme can continue.
Broader Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court suspended a similar health funding agreement following concerns were raised about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information indefinitely, without any corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"In essence, our country would supply the basic resources for medical research with no certainty that the end products would be accessible to our people if a future disease outbreak arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending frameworks previously set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This framework is intended to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued discussions with our US partners on how future co-operation might be structured in a manner that respects the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but urged that talks need to persist since much of the nation's HIV programmes depended on foreign aid.
"If technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group said.
The halted deal underscores the ongoing debate between receiving crucial foreign assistance and protecting a country's data in an ever more interconnected world.